Form 4: OptimizeRx CBO Sells Shares for Tax Obligations

OptimizeRx Chief Business Officer Andrew J. D'Silva disposed of 703 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Andrew J. D'Silva, Chief Business Officer of OptimizeRx Corp (OPRX), disposed of 703 shares of common stock.
• The transaction occurred on December 19, 2025, at a price of $13.51 per share.
• These shares were withheld by OptimizeRx to satisfy tax withholding obligations upon the vesting of restricted stock units.
• Following this transaction, D'Silva beneficially owns 44,735 shares of OptimizeRx common stock.

Sentiment

Score: 5

Explanation: The transaction is a standard tax-related disposition following RSU vesting, not indicative of positive or negative sentiment towards the company's future.

Positives

• The transaction stems from the vesting of restricted stock units, indicating the executive has earned compensation.

Negatives

• The disposition of 703 shares reduces the direct beneficial ownership of the Chief Business Officer in OptimizeRx Corp.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to OptimizeRx Corp and its Chief Business Officer, Andrew J. D'Silva, and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders will note a minor reduction in direct insider ownership, but this is a routine event for tax purposes and is unlikely to have a significant impact on investor perception.

Key Dates

Recommendation

The reported transaction is a routine disposition of shares by an officer to cover tax obligations upon the vesting of restricted stock units. This type of insider transaction is common and does not typically signal a change in the company's fundamentals or the officer's long-term view of the company, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

OptimizeRx, OPRX, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, Andrew J. D'Silva